A Single-centre, Open-label, Sequential Ascending Cross Over Study to Examine Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Ascending Single Doses, Nominally 10, 30, 70 and 110µg Intravenous Doses and a Single 250µg Oral Dose of GSK233705 in Healthy Volunteers.
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Darotropium bromide (Primary) ; Darotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GSK
- 12 Jun 2008 Patient numbers amended from 7 to 9 as reported by ClinicalTrials.gov
- 12 Jun 2008 Actual end date for this trial is now Jul 2007 as reported by ClinicalTrials.gov
- 12 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov